Predict your next investment

Corporation
zapigroup.com

See what CB Insights has to offer

About ZAPI

ZAPI is a manufacturer of electronic speed controllers, electric motors, battery chargers, and electric power steering solutions for electric and hybrid vehicles.

ZAPI Headquarter Location

via Parma 59

Poviglio, 42028,

Italy

+39 0522 960050

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest ZAPI News

Dyadic’s C1 Production Platform Utilized in ZAPI Study Published in “VACCINES” a Leading Peer-Reviewed Scientific Journal

Jun 28, 2021

Jupiter, Florida, UNITED STATES Dyadic’s C1-cell protein production platform selected as a fast response vaccine manufacturing model against zoonotic diseases. C1 -cell platform expressed SBV antigen exhibited efficacy, potency, and safety in veterinary target species. Demonstrated recombinant protein-based antigens can be produced from C1-cells at very high yields. C1-cell expressed antigens were successfully used to develop recombinant particle-display vaccines. JUPITER, Fla., June 28, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs, announced today findings from the Zoonotic Anticipation and Preparedness Initiative (ZAPI) project which has been published in VACCINES, a leading peer-reviewed scientific journal. “Zoonotic diseases represent a serious global threat to human and animal health. The majority of newly evolving pathogens are zoonotic viruses. Safe and effective vaccines that can be developed rapidly following an outbreak are required to effectively combat these diseases. The efficacy, protection and safety data reported from the ZAPI study further supports the mounting library of data – demonstrating a novel approach for the C1 expression platform to be broadly applied for rapid development and manufacturing of vaccines for both human and animals”. Dr. Tchelet further commented “we anticipate additional partnerships and external collaborations which will serve to further advance our commercial objectives”. The successful ZAPI program focused on the following goals to enable the delivery of targeted vaccines for humans and animals, as well as therapeutic antibodies for hospital use, rapidly following a future disease outbreak by: Identifying the best protective subunit vaccines and neutralizing antibodies against potential new zoonotic diseases or strains, such as bunyaviruses (i.e., Rift Valley fever virus and Schmallenberg virus) or coronaviruses (i.e., Middle East respiratory syndrome coronavirus or MERS Co-V). Defining optimal manufacturing technologies and processes for these vaccines and antibodies to enable high-volume production capacity. Obtaining alignment with regulatory authorities and policy makers; and Securing pre-approval of new vaccine and antibody manufacturing methodologies for future emerging zoonotic viral diseases. The peer-reviewed study demonstrates the successful use of Dyadic’s patented and proprietary C1-cell protein production platform to facilitate a fast, coordinated, and practical response to new infectious diseases as soon as they emerge. Dr Jean-Christophe Audonnet, Senior Director Regional R&D Asia & EU Partnerships, IMI ZAPI Project Coordinator commented, “The sterile protection obtained in the cattle target species for the ZAPI Schmallenberg model vaccine indicated quite clearly that the SBV Gc subunit expressed from the C1 fungus system was as good, if not better, than subunits expressed from more classical systems. The immunogenicity of C1-cell expressed Gc subunits looks excellent, even at a low dose of 50 µg. Moreover, the very high yield that can be provided by C1 cell lines makes it the platform of choice when there is a need for large amounts of vaccine doses, at a cost compatible with human and animal health vaccine applications.” Dr. Audonnet continued, "Dyadic and its C1-cell protein production platform far exceeded our initial expectations at the start of the program.” A link to the scientific publication as published in the peer reviewed journal “VACCINES” can be found below:

ZAPI Acquisitions

1 Acquisition

ZAPI acquired 1 company. Their latest acquisition was Delta-Q Technologies on December 07, 2016.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

12/7/2016

Growth Equity

$17M

Acquired

1

Date

12/7/2016

Investment Stage

Growth Equity

Companies

Valuation

Total Funding

$17M

Note

Acquired

Sources

1

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.